共 45 条
- [32] Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (03) : 237 - 244
- [33] Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis European Journal of Clinical Microbiology & Infectious Diseases, 2017, 36 : 1057 - 1062
- [37] Safety of Palivizumab in Preterm Infants 29 to 32 Weeks' Gestational Age Without Chronic Lung Disease to Prevent Serious Respiratory Syncytial Virus Infection European Journal of Clinical Microbiology and Infectious Diseases , 2003, 22 : 414 - 417